LAVAL, Quebec, April 5 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that Mark D’Souza, Chief Financial Officer of the Company, will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference in New York, on Wednesday, April 11, 2007 at 3:05 p.m. ET.
About Labopharm Inc.
Labopharm Inc. is an international specialty pharmaceutical company focused on the development of drugs incorporating the Company’s proprietary advanced controlled-release technologies. The Company’s lead product, a once-daily formulation of the analgesic tramadol, has been approved and launched in Europe and is currently under review for approval by the U.S. Food and Drug Administration. For more information, please visit www.labopharm.com.
This press release contains forward-looking statements, which reflect the Corporation’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process and the commercialization of the Corporation’s products thereafter, if they are approved. Investors should consult the Corporation’s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Corporation disclaims any obligation to update these forward-looking statements.
Labopharm Inc.
CONTACT: At Labopharm, Mark D’Souza, Chief Financial Officer, Tel: (450)686-0207; At The Equicom Group, Jason Hogan, Media and Investor Relations,Tel: (416) 815-0700, jhogan@equicomgroup.com; French: Eric Bouchard, Tel:(514) 844-7997, ebouchard@equicomgroup.com
